Last updated: September 8, 2026
Omacetaxine mepesuccinate, marketed in the United States as Synribo by Teva Pharmaceuticals, is a niche treatment for adults with chronic-phase or accelerated-phase chronic myeloid leukemia who have resistance or intolerance to at least two tyrosine kinase inhibitors. FDA approval in 2012 created a limited commercial opportunity because the drug addressed a heavily pretreated population, required subcutaneous administration, and competed with increasingly effective next-generation TKIs.
The product’s commercial trajectory has been constrained by its narrow label, administration burden, modest adoption, and the expanding efficacy of alternative CML therapies. Teva has not historically disclosed Synribo revenue as a separate material reporting line. Public financial information therefore supports a directional conclusion rather than a precise standalone revenue model: Synribo progressed from a niche launch to a low-scale product with limited strategic importance in Teva’s portfolio.
What is omacetaxine mepesuccinate and how does it work?
Omacetaxine mepesuccinate is a subcutaneously administered formulation of omacetaxine, a protein-synthesis inhibitor derived from homoharringtonine. It acts independently of BCR::ABL kinase inhibition, making it mechanistically distinct from imatinib, dasatinib, nilotinib, bosutinib, and ponatinib.
The drug is supplied as a 3.5-mg lyophilized powder for reconstitution. The labeled regimen includes induction dosing of 1.25 mg/m² twice daily for 14 consecutive days in a 28-day cycle, followed by maintenance dosing twice daily for seven consecutive days in a 28-day cycle. Treatment continues while clinical benefit remains and toxicity is manageable.[1]
The principal safety liabilities are:
- Thrombocytopenia
- Neutropenia
- Anemia
- Hyperglycemia
- Injection-site reactions
- Fatigue
- Gastrointestinal adverse events
These requirements reduce convenience relative to oral TKIs and increase the need for blood-count monitoring.
When did the FDA approve Synribo?
The FDA approved Synribo on October 26, 2012, under the accelerated approval pathway for adults with chronic-phase or accelerated-phase CML who had resistance or intolerance to at least two TKIs.[2]
The approval was based primarily on major cytogenetic response data from a single-arm clinical development program. The product entered a treatment segment defined by failure of multiple prior therapies, including patients with limited remaining options.
FDA regulatory profile
| Attribute |
Omacetaxine mepesuccinate |
| Brand |
Synribo |
| Active ingredient |
Omacetaxine mepesuccinate |
| Sponsor at U.S. approval |
Teva Pharmaceuticals |
| FDA approval date |
October 26, 2012 |
| Dosage form |
Subcutaneous injection |
| Indication |
Chronic-phase or accelerated-phase CML after resistance or intolerance to at least two TKIs |
| Regulatory pathway |
Accelerated approval |
| Therapeutic class |
Protein-synthesis inhibitor |
| Primary commercial market |
Heavily pretreated adult CML |
| Biosimilar pathway |
Not applicable |
Omacetaxine is a small molecule, not a biologic. Any follow-on competitor would generally use the abbreviated new drug application pathway rather than the biosimilar pathway.
How large is the market for omacetaxine mepesuccinate?
The addressable market is structurally small. CML is a relatively uncommon leukemia, and modern TKIs allow many patients to remain on long-term oral therapy. Omacetaxine is positioned after failure or intolerance of at least two TKIs, which sharply narrows the eligible population.
The drug’s market is also affected by treatment sequencing:
- First-line use is dominated by TKIs.
- Second-line treatment commonly remains within the TKI class.
- Mutation-guided therapy may direct patients to ponatinib or asciminib.
- Omacetaxine is generally considered after multiple prior therapies or when other options are unsuitable.
Asciminib, approved by the FDA in 2021 for patients previously treated with at least two TKIs and later expanded to earlier-line use, created a direct competitive pressure in the same treatment-experienced CML segment.[3] Its oral administration and targeted mechanism improve its commercial positioning against an injectable cytotoxic agent.
What drugs compete with omacetaxine in CML?
Omacetaxine competes with both branded and generic TKIs. The principal alternatives include:
| Competitor |
Mechanism |
Commercial effect on omacetaxine |
| Imatinib |
BCR::ABL TKI |
Low-cost generic option; limits use outside refractory disease |
| Dasatinib |
BCR::ABL TKI |
Established second-line and later-line alternative |
| Nilotinib |
BCR::ABL TKI |
Long-standing branded and generic competition |
| Bosutinib |
BCR::ABL TKI |
Later-line oral treatment option |
| Ponatinib |
BCR::ABL TKI |
Important option for resistant disease and T315I mutations |
| Asciminib |
STAMP inhibitor |
Directly competes for patients after prior TKI exposure |
| Allogeneic stem-cell transplant |
Curative-intent intervention |
Relevant for selected high-risk or refractory patients |
The competitive gap narrowed after the introduction of asciminib. Before asciminib, omacetaxine’s non-TKI mechanism had greater importance for patients who had exhausted or could not tolerate several TKIs. Asciminib provided another oral, targeted option for many of those patients.
What was the financial trajectory of Synribo?
Teva has not provided a consistently reported standalone annual revenue series for Synribo in its principal public financial statements. The company generally reports revenue by broader product categories, geographies, or business segments rather than publishing a separate Synribo income statement.
The financial trajectory can therefore be assessed through four commercial indicators:
- Narrow eligible population
- Limited treatment duration in heavily pretreated patients
- Administration and monitoring burden
- Intensifying competition from later-generation TKIs
Synribo’s commercial model was unlikely to support large-scale revenue because the product was not used broadly across the CML population. It was a rescue or later-line therapy rather than a front-line platform product. The product also lacked the recurring-volume potential of oral TKIs prescribed for many years.
Revenue exposure for Teva
Synribo represented a limited share of Teva’s total revenue compared with major products such as Copaxone, Ajovy, Austedo, and large generic portfolios. Teva’s annual reports did not identify Synribo as a material revenue concentration or a major driver of consolidated performance.[4]
This limited revenue exposure reduced the financial cost of declining demand or a U.S. commercial discontinuation. It also reduced Teva’s incentive to invest heavily in expanded indications, new delivery systems, or broad lifecycle management.
Has Teva discontinued Synribo in the United States?
Public FDA and commercial product information indicates that Synribo is no longer an actively marketed U.S. product. The commercial discontinuation is consistent with low demand, a narrow treatment population, and competitive displacement rather than a safety-driven regulatory withdrawal.
A product discontinuation does not automatically mean that the FDA has withdrawn the approval. FDA records distinguish between an approved product that is no longer marketed and a product removed from the market for safety or efficacy reasons.[5]
The practical commercial result is similar for U.S. patients: access depends on remaining inventory, manufacturer arrangements, or treatment alternatives. The market value of the U.S. brand therefore declines even if the underlying NDA remains in FDA records.
What patents protect omacetaxine mepesuccinate?
The commercial protection for omacetaxine has historically involved product, formulation, manufacturing, and use-related intellectual property. The most commercially relevant claims would cover:
- Omacetaxine compositions
- Injectable formulations
- Lyophilized dosage forms
- Methods of treating CML after TKI failure
- Dosing schedules and administration protocols
- Manufacturing or purification processes
The core active ingredient is an older natural-product-derived compound, so exclusivity depends less on a new molecular entity patent than on later-issued formulation, use, and regulatory protections.
Orange Book status
The FDA Orange Book is the controlling source for current U.S. patent and exclusivity listings for approved drug products. Synribo’s commercial status should be evaluated separately from the continuing existence of its NDA. An approved NDA may remain listed even when the product is no longer sold.
There is no established commercial basis for treating omacetaxine as a current high-value patent battleground. The product’s small market, declining commercial status, and lack of a significant branded growth strategy reduce the economic incentive for extensive patent enforcement.
Are there Paragraph IV challenges or generic entry risks?
Omacetaxine is subject to the small-molecule generic pathway. A competing manufacturer could submit an ANDA with a Paragraph IV certification against listed patents, or a Paragraph III certification if the relevant patents had expired.
The key generic-entry considerations are:
- Injectable manufacturing complexity
- Reconstitution and stability requirements
- Limited market size
- Potentially low return on development investment
- Reduced need for a generic if the branded product is no longer commercially active
- Possible availability of alternative oral therapies
Publicly visible market information does not establish a major ongoing Paragraph IV litigation campaign involving Synribo. The absence of a prominent generic competitor is commercially explainable without assuming strong patent protection. A small, technically complex injectable market can remain unserved because expected sales do not justify development and regulatory costs.
What manufacturing barriers affect omacetaxine?
Omacetaxine is more difficult to commercialize than a conventional oral tablet. Manufacturing and supply considerations include:
- Active pharmaceutical ingredient sourcing
- Control of natural-product-derived starting materials
- Purity and impurity specifications
- Sterile manufacturing
- Lyophilization
- Container-closure integrity
- Reconstitution performance
- Cold-chain or controlled storage requirements, depending on the presentation
- Quality control for a cytotoxic injectable product
These barriers can protect a niche supplier from immediate competition even when composition-of-matter exclusivity is limited. They do not, however, compensate for a small patient pool and weak commercial demand.
Which companies are challenging omacetaxine commercially?
The principal commercial challengers are not necessarily generic manufacturers. They are companies selling alternative CML therapies:
- Novartis, through imatinib and nilotinib
- Bristol Myers Squibb, through dasatinib
- Pfizer, through bosutinib
- Takeda, through ponatinib
- Novartis, through asciminib
- Multiple generic manufacturers selling imatinib and other TKIs
Asciminib is the most strategically important branded competitor because it targets a treatment-experienced CML population and is administered orally. Generic imatinib exerts price pressure across the disease market, even though it is not a direct substitute for every resistant or intolerant patient.
How strong is the omacetaxine patent estate?
The patent estate is commercially weak relative to newer branded oncology products. Its limitations are structural:
- The active ingredient is not a recent discovery.
- The approved indication is narrow.
- The product has limited lifecycle expansion opportunities.
- Oral targeted competitors have improved the treatment environment.
- The manufacturer’s commercial commitment appears limited.
- The remaining market is too small to support aggressive exclusivity monetization.
Formulation and method-of-use patents may have delayed direct substitution during the product’s commercial period. They are less likely to create substantial present-day value if the branded product is no longer actively marketed in the United States.
What are the likely generic launch scenarios?
Scenario 1: No generic launch
This is the most commercially plausible outcome if the U.S. market remains small or inactive. A generic manufacturer may prioritize larger oncology injectables with clearer volume potential.
Scenario 2: Single-source niche generic
A specialist injectable manufacturer could enter if it identifies stable institutional demand, favorable pricing, or an opportunity to supply markets underserved by the former branded product.
Scenario 3: Limited geographic launch
A manufacturer may pursue selected non-U.S. markets rather than a broad global launch. Commercial viability would depend on local pricing, reimbursement, regulatory requirements, and access to sterile manufacturing capacity.
Scenario 4: Therapeutic displacement without generic substitution
Patients may move directly to asciminib, ponatinib, bosutinib, clinical trials, or transplantation rather than to a generic version of omacetaxine. This scenario limits the value of omacetaxine-related manufacturing rights even if no patent blocks entry.
What is the outlook for omacetaxine mepesuccinate?
Omacetaxine’s outlook is defensive rather than growth-oriented. The product retains mechanistic relevance for selected CML patients who cannot use or do not respond adequately to TKIs. Its commercial prospects are limited by the size of that population and by the availability of oral targeted treatments.
The product may retain value in:
- Countries where later-generation TKIs are unavailable or unaffordable
- Patients with intolerance to multiple TKIs
- Patients with complex resistance profiles
- Institutional or compassionate-use settings
- Markets where a specialist manufacturer can operate with low overhead
The U.S. opportunity is materially weaker than the original post-approval opportunity. The main value now lies in specialized access, manufacturing know-how, and possible geographic licensing rather than in a large branded revenue stream.
Key Takeaways
- Omacetaxine mepesuccinate is a subcutaneous, non-TKI treatment for heavily pretreated CML.
- FDA approval occurred in 2012 for adults with chronic- or accelerated-phase CML after resistance or intolerance to at least two TKIs.
- Synribo addressed a small rescue-therapy market and never became a major Teva revenue contributor.
- Asciminib and other oral TKIs weakened omacetaxine’s competitive position.
- Teva has not disclosed a reliable standalone Synribo revenue series.
- The product’s small-molecule status permits generic competition through the ANDA pathway, not the biosimilar pathway.
- Sterile injectable manufacturing creates practical entry barriers, but those barriers may not justify development for a small market.
- The current commercial opportunity is more likely to involve niche supply or geographic licensing than U.S. brand growth.
- Patent value is limited by the age of the active ingredient, narrow indication, and reduced commercial activity.
FAQs
Is omacetaxine mepesuccinate still FDA approved?
The FDA approval for Synribo remains distinct from commercial availability. A product can remain in FDA records while no longer being actively marketed in the United States.
Is omacetaxine a chemotherapy drug or a targeted therapy?
Omacetaxine is an antineoplastic protein-synthesis inhibitor. It is not a BCR::ABL kinase inhibitor and is pharmacologically distinct from targeted TKIs such as imatinib and asciminib.
Can omacetaxine be used before a patient tries multiple TKIs?
The labeled U.S. indication is for adults with chronic-phase or accelerated-phase CML who have resistance or intolerance to at least two TKIs. Earlier use would require a different regulatory basis or clinical-trial setting.
Does omacetaxine have biosimilar competition?
No. Biosimilar rules apply to biologic products. Omacetaxine is a small molecule and would be challenged through the generic-drug pathway.
Could omacetaxine regain commercial value outside the United States?
Potentially, but the opportunity would depend on local CML treatment standards, access to TKIs, reimbursement, sterile manufacturing economics, and regulatory approval. The strongest opportunity would be in markets where later-generation oral alternatives are limited.
References
- U.S. Food and Drug Administration. (2020). Synribo (omacetaxine mepesuccinate) prescribing information.
- U.S. Food and Drug Administration. (2012, October 26). FDA approves Synribo for chronic myeloid leukemia.
- U.S. Food and Drug Administration. (2021, October 29). FDA approves asciminib for chronic myeloid leukemia.
- Teva Pharmaceutical Industries Ltd. (2013–2023). Annual reports and Form 20-F filings.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs and discontinued drug products.
